Do analysts recommend VGW or HLS?

HLS Therapeutics has a consensus target price of C$8.00, suggesting a potential upside of 122.22%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe HLS Therapeutics is more favorable than Valens GroWorks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valens GroWorks 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 HLS Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50

Do analysts rate VBV or HLS?

HLS Therapeutics has a consensus target price of C$8.00, indicating a potential upside of 122.22%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe HLS Therapeutics is more favorable than VBI Vaccines. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VBI Vaccines 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 HLS Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50

Which has better earnings & valuation, VBV or HLS?

HLS Therapeutics has higher revenue and earnings than VBI Vaccines. HLS Therapeutics is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VBI Vaccines C$3.36M 0.00 -C$62.16M -C$0.97 N/A HLS Therapeutics C$56.24M 1.98 -C$15.53M -C$0.27 N/A

Do analysts rate HLS or CRDL?

HLS Therapeutics currently has a consensus price target of C$8.00, suggesting a potential upside of 122.22%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe HLS Therapeutics is more favorable than Cardiol Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HLS Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

HLS Therapeutics (HLS) Competitors

C$3.60 -0.01 (-0.28%)

As of 09/3/2026 03:59 PM Eastern

Compare

HLS vs. VGW, CPH, ACB, VBV, and CRDL

Should you buy HLS Therapeutics stock or one of its competitors? HLS Therapeutics's main competitors and comparable companies include Valens GroWorks (VGW), Cipher Pharmaceuticals (CPH), Aurora Cannabis (ACB), VBI Vaccines (VBV), and Cardiol Therapeutics (CRDL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does HLS Therapeutics compare to Valens GroWorks?

Valens GroWorks (CVE:VGW) and HLS Therapeutics (TSE:HLS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

In the previous week, Valens GroWorks' average media sentiment score of 0.00 equaled HLS Therapeutics'average media sentiment score.

Company	Overall Sentiment
Valens GroWorks	Neutral
HLS Therapeutics	Neutral

6.1% of HLS Therapeutics shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valens GroWorks has a net margin of 0.00% compared to HLS Therapeutics' net margin of -15.26%. Valens GroWorks' return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valens GroWorks	N/A	N/A	N/A
HLS Therapeutics	-15.26%	-14.39%	-2.89%

HLS Therapeutics has a consensus target price of C$8.00, suggesting a potential upside of 122.22%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe HLS Therapeutics is more favorable than Valens GroWorks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valens GroWorks	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
HLS Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

HLS Therapeutics has higher revenue and earnings than Valens GroWorks. Valens GroWorks is trading at a lower price-to-earnings ratio than HLS Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valens GroWorks	C$27.50M	13.96	-C$22.41M	-C$0.18	N/A
HLS Therapeutics	C$56.24M	1.98	-C$15.53M	-C$0.27	N/A

Summary

HLS Therapeutics beats Valens GroWorks on 9 of the 14 factors compared between the two stocks.

How does HLS Therapeutics compare to Cipher Pharmaceuticals?

HLS Therapeutics (TSE:HLS) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

HLS Therapeutics has a beta of -0.484581, indicating that its stock price is 148% less volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.153789, indicating that its stock price is 15% more volatile than the broader market.

Cipher Pharmaceuticals has a net margin of 58.81% compared to HLS Therapeutics' net margin of -15.26%. Cipher Pharmaceuticals' return on equity of 22.74% beat HLS Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HLS Therapeutics	-15.26%	-14.39%	-2.89%
Cipher Pharmaceuticals	58.81%	22.74%	7.90%

Cipher Pharmaceuticals has lower revenue, but higher earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HLS Therapeutics	C$56.24M	1.98	-C$15.53M	-C$0.27	N/A
Cipher Pharmaceuticals	C$49.62M	7.37	C$11.41M	C$1.12	12.85

In the previous week, Cipher Pharmaceuticals had 2 more articles in the media than HLS Therapeutics. MarketBeat recorded 2 mentions for Cipher Pharmaceuticals and 0 mentions for HLS Therapeutics. Cipher Pharmaceuticals' average media sentiment score of 0.59 beat HLS Therapeutics' score of 0.00 indicating that Cipher Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
HLS Therapeutics	Neutral
Cipher Pharmaceuticals	Positive

6.1% of HLS Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by company insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

HLS Therapeutics currently has a consensus target price of C$8.00, indicating a potential upside of 122.22%. Cipher Pharmaceuticals has a consensus target price of C$17.00, indicating a potential upside of 18.14%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe HLS Therapeutics is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HLS Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cipher Pharmaceuticals beats HLS Therapeutics on 11 of the 17 factors compared between the two stocks.

How does HLS Therapeutics compare to Aurora Cannabis?

Aurora Cannabis (TSE:ACB) and HLS Therapeutics (TSE:HLS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Aurora Cannabis has a beta of 0.246838, meaning that its share price is 75% less volatile than the broader market. Comparatively, HLS Therapeutics has a beta of -0.484581, meaning that its share price is 148% less volatile than the broader market.

HLS Therapeutics has lower revenue, but higher earnings than Aurora Cannabis. HLS Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	C$314.07M	1.06	-C$44.16M	-C$1.94	N/A
HLS Therapeutics	C$56.24M	1.98	-C$15.53M	-C$0.27	N/A

Aurora Cannabis has a net margin of -9.53% compared to HLS Therapeutics' net margin of -15.26%. Aurora Cannabis' return on equity of -5.21% beat HLS Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-9.53%	-5.21%	-1.87%
HLS Therapeutics	-15.26%	-14.39%	-2.89%

4.1% of Aurora Cannabis shares are held by institutional investors. Comparatively, 6.1% of HLS Therapeutics shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aurora Cannabis currently has a consensus price target of C$6.20, indicating a potential upside of 15.46%. HLS Therapeutics has a consensus price target of C$8.00, indicating a potential upside of 122.22%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe HLS Therapeutics is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
HLS Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

In the previous week, Aurora Cannabis had 5 more articles in the media than HLS Therapeutics. MarketBeat recorded 5 mentions for Aurora Cannabis and 0 mentions for HLS Therapeutics. HLS Therapeutics' average media sentiment score of 0.00 beat Aurora Cannabis' score of -1.09 indicating that HLS Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aurora Cannabis	Negative
HLS Therapeutics	Neutral

Summary

HLS Therapeutics beats Aurora Cannabis on 9 of the 17 factors compared between the two stocks.

How does HLS Therapeutics compare to VBI Vaccines?

VBI Vaccines (TSE:VBV) and HLS Therapeutics (TSE:HLS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

In the previous week, VBI Vaccines' average media sentiment score of 0.00 equaled HLS Therapeutics'average media sentiment score.

Company	Overall Sentiment
VBI Vaccines	Neutral
HLS Therapeutics	Neutral

HLS Therapeutics has higher revenue and earnings than VBI Vaccines. HLS Therapeutics is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VBI Vaccines	C$3.36M	0.00	-C$62.16M	-C$0.97	N/A
HLS Therapeutics	C$56.24M	1.98	-C$15.53M	-C$0.27	N/A

VBI Vaccines has a net margin of 0.00% compared to HLS Therapeutics' net margin of -15.26%. VBI Vaccines' return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VBI Vaccines	N/A	N/A	N/A
HLS Therapeutics	-15.26%	-14.39%	-2.89%

HLS Therapeutics has a consensus target price of C$8.00, indicating a potential upside of 122.22%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe HLS Therapeutics is more favorable than VBI Vaccines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VBI Vaccines	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
HLS Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

6.1% of HLS Therapeutics shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

HLS Therapeutics beats VBI Vaccines on 9 of the 13 factors compared between the two stocks.

How does HLS Therapeutics compare to Cardiol Therapeutics?

HLS Therapeutics (TSE:HLS) and Cardiol Therapeutics (TSE:CRDL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

HLS Therapeutics has higher revenue and earnings than Cardiol Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HLS Therapeutics	C$56.24M	1.98	-C$15.53M	-C$0.27	N/A
Cardiol Therapeutics	N/A	N/A	-C$42.93M	-C$0.34	N/A

HLS Therapeutics has a beta of -0.484581, meaning that its share price is 148% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.270267, meaning that its share price is 73% less volatile than the broader market.

HLS Therapeutics currently has a consensus price target of C$8.00, suggesting a potential upside of 122.22%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe HLS Therapeutics is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HLS Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Cardiol Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cardiol Therapeutics has a net margin of 0.00% compared to HLS Therapeutics' net margin of -15.26%. HLS Therapeutics' return on equity of -14.39% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HLS Therapeutics	-15.26%	-14.39%	-2.89%
Cardiol Therapeutics	N/A	-180.13%	-54.15%

6.1% of HLS Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Cardiol Therapeutics shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by insiders. Comparatively, 4.6% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, HLS Therapeutics' average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score.

Company	Overall Sentiment
HLS Therapeutics	Neutral
Cardiol Therapeutics	Neutral

Summary

HLS Therapeutics beats Cardiol Therapeutics on 10 of the 14 factors compared between the two stocks.

Get HLS Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HLS vs. The Competition

Export

Metric	HLS Therapeutics	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$111.68M	C$12.25B	C$7.26B	C$12.57B
Dividend Yield	4.30%	2.59%	2.53%	6.25%
P/E Ratio	-13.33	787.27	273.29	39.47
Price / Sales	1.98	754.88	623.67	9.82
Price / Cash	15.22	94.80	77.82	82.29
Price / Book	2.04	12.33	12.92	4.71
Net Income	-C$15.53M	C$2.82B	C$3.47B	C$299.09M
7 Day Performance	-5.01%	2.60%	0.60%	-0.31%
1 Month Performance	-12.62%	6.96%	5.72%	3.12%
1 Year Performance	-34.90%	9.45%	25.33%	28.73%

HLS Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HLS HLS Therapeutics	N/A	C$3.60 -0.3%	C$8.00 +122.2%	-33.7%	C$111.68M	C$56.24M	N/A	91
VGW Valens GroWorks	N/A	C$3.10 +1.6%	N/A	+0.0%	C$383.88M	C$27.50M	N/A	N/A
CPH Cipher Pharmaceuticals	1.5698 of 5 stars	C$14.10 -1.5%	C$17.00 +20.6%	-9.2%	C$358.35M	C$49.62M	12.59	5
ACB Aurora Cannabis	1.4182 of 5 stars	C$5.41 +3.0%	C$6.20 +14.6%	-20.7%	C$335.19M	C$314.07M	N/A	1,073	Negative News
VBV VBI Vaccines	N/A	N/A	N/A	N/A	C$308.86M	C$3.36M	N/A	22

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:HLS) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HLS Therapeutics (HLS) Competitors

HLS vs. VGW, CPH, ACB, VBV, and CRDL

How does HLS Therapeutics compare to Valens GroWorks?

Summary

How does HLS Therapeutics compare to Cipher Pharmaceuticals?

Summary

How does HLS Therapeutics compare to Aurora Cannabis?

Summary

How does HLS Therapeutics compare to VBI Vaccines?

Summary

How does HLS Therapeutics compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLS vs. The Competition

HLS Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HLS Therapeutics (HLS) Competitors

HLS vs. VGW, CPH, ACB, VBV, and CRDL

How does HLS Therapeutics compare to Valens GroWorks?

Does the media refer more to VGW or HLS?

Do insiders & institutionals hold more shares of VGW or HLS?

Is VGW or HLS more profitable?

Do analysts recommend VGW or HLS?

Which has higher earnings & valuation, VGW or HLS?

Summary

How does HLS Therapeutics compare to Cipher Pharmaceuticals?

Which has more risk and volatility, HLS or CPH?

Is HLS or CPH more profitable?

Which has better valuation & earnings, HLS or CPH?

Does the media favor HLS or CPH?

Do institutionals & insiders hold more shares of HLS or CPH?

Do analysts rate HLS or CPH?

Summary

How does HLS Therapeutics compare to Aurora Cannabis?

Which has more volatility and risk, ACB or HLS?

Which has stronger valuation and earnings, ACB or HLS?

Is ACB or HLS more profitable?

Do institutionals and insiders believe in ACB or HLS?

Do analysts rate ACB or HLS?

Does the media refer more to ACB or HLS?

Summary

How does HLS Therapeutics compare to VBI Vaccines?

Does the media favor VBV or HLS?

Which has better earnings & valuation, VBV or HLS?

Is VBV or HLS more profitable?

Do analysts rate VBV or HLS?

Do insiders and institutionals believe in VBV or HLS?

Summary

How does HLS Therapeutics compare to Cardiol Therapeutics?

Which has preferable earnings & valuation, HLS or CRDL?

Which has more risk and volatility, HLS or CRDL?

Do analysts rate HLS or CRDL?

Is HLS or CRDL more profitable?

Do insiders & institutionals hold more shares of HLS or CRDL?

Does the media prefer HLS or CRDL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLS vs. The Competition

HLS Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools